Global Targeted Drugs for Neurodegenerative Diseases Market Growth (Status and Outlook) 2026-2032
The global Targeted Drugs for Neurodegenerative Diseases market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Targeted Drugs for Neurodegenerative Diseases players cover Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Targeted Drugs for Neurodegenerative Diseases Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Neurodegenerative Diseases sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Neurodegenerative Diseases sales for 2026 through 2032. With Targeted Drugs for Neurodegenerative Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Neurodegenerative Diseases industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Neurodegenerative Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Neurodegenerative Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Neurodegenerative Diseases market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Neurodegenerative Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Neurodegenerative Diseases.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Neurodegenerative Diseases market by product type, application, key players and key regions and countries.
Segmentation by Type:
United States market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Targeted Drugs for Neurodegenerative Diseases players cover Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Targeted Drugs for Neurodegenerative Diseases Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Neurodegenerative Diseases sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Neurodegenerative Diseases sales for 2026 through 2032. With Targeted Drugs for Neurodegenerative Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Neurodegenerative Diseases industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Neurodegenerative Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Neurodegenerative Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Neurodegenerative Diseases market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Neurodegenerative Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Neurodegenerative Diseases.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Neurodegenerative Diseases market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Injection
- Oral
- Parkinson's Disease (PD)
- Alzheimer's Disease (AD)
- Huntington's Disease (HD)
- Tardive Dyskinesia (TD)
- Multiple Sclerosis (MS)
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Acadia Pharmaceuticals Inc.
- Kyowa Kirin
- Supernus Pharmaceuticals
- UCB
- Sumitomo Pharma
- Biogen
- Eisai Inc.
- Eli Lilly
- Green Valley
- NOVARTIS
- Bristol-Myers Squibb
- Janssen
- Sanofi
- Roche
- Neurocrine
- Lundbeck
- Teva
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)
2.1.2 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted Drugs for Neurodegenerative Diseases by Country/Region (2021, 2025 & 2032)
2.2 Targeted Drugs for Neurodegenerative Diseases Segment by Type
2.2.1 Injection
2.2.2 Oral
2.2.3 Targeted Drugs for Neurodegenerative Diseases Market Size by Type
2.2.3.1 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
2.3 Targeted Drugs for Neurodegenerative Diseases Segment by Application
2.3.1 Parkinson's Disease (PD)
2.3.2 Alzheimer's Disease (AD)
2.3.3 Huntington's Disease (HD)
2.3.4 Tardive Dyskinesia (TD)
2.3.5 Multiple Sclerosis (MS)
2.3.6 Targeted Drugs for Neurodegenerative Diseases Market Size by Application
2.3.6.1 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.6.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
3 TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES MARKET SIZE BY PLAYER
3.1 Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Player
3.1.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Player (2021-2026)
3.1.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
3.2 Global Targeted Drugs for Neurodegenerative Diseases Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES BY REGION
4.1 Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026)
4.2 Global Targeted Drugs for Neurodegenerative Diseases Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.4 APAC Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.5 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
5.2 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
5.3 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026)
6.2 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
6.3 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
7.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases by Region (2021-2026)
8.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES MARKET FORECAST
10.1 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.1 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.2 Americas Targeted Drugs for Neurodegenerative Diseases Forecast
10.1.3 APAC Targeted Drugs for Neurodegenerative Diseases Forecast
10.1.4 Europe Targeted Drugs for Neurodegenerative Diseases Forecast
10.1.5 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Forecast
10.2 Americas Targeted Drugs for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.2.1 United States Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.2.2 Canada Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.2.3 Mexico Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.2.4 Brazil Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3 APAC Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.3.1 China Targeted Drugs for Neurodegenerative Diseases Market Forecast
10.3.2 Japan Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.3 Korea Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.4 Southeast Asia Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.5 India Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.6 Australia Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4 Europe Targeted Drugs for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.2 France Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.3 UK Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.4 Italy Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.5 Russia Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5.2 South Africa Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5.3 Israel Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5.4 Turkey Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.6 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Type (2027-2032)
10.7 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted Drugs for Neurodegenerative Diseases Forecast
11 KEY PLAYERS ANALYSIS
11.1 Acadia Pharmaceuticals Inc.
11.1.1 Acadia Pharmaceuticals Inc. Company Information
11.1.2 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Acadia Pharmaceuticals Inc. Main Business Overview
11.1.5 Acadia Pharmaceuticals Inc. Latest Developments
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Company Information
11.2.2 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Offered
11.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Kyowa Kirin Main Business Overview
11.2.5 Kyowa Kirin Latest Developments
11.3 Supernus Pharmaceuticals
11.3.1 Supernus Pharmaceuticals Company Information
11.3.2 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Offered
11.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Supernus Pharmaceuticals Main Business Overview
11.3.5 Supernus Pharmaceuticals Latest Developments
11.4 UCB
11.4.1 UCB Company Information
11.4.2 UCB Targeted Drugs for Neurodegenerative Diseases Product Offered
11.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 UCB Main Business Overview
11.4.5 UCB Latest Developments
11.5 Sumitomo Pharma
11.5.1 Sumitomo Pharma Company Information
11.5.2 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Offered
11.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Sumitomo Pharma Main Business Overview
11.5.5 Sumitomo Pharma Latest Developments
11.6 Biogen
11.6.1 Biogen Company Information
11.6.2 Biogen Targeted Drugs for Neurodegenerative Diseases Product Offered
11.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Biogen Main Business Overview
11.6.5 Biogen Latest Developments
11.7 Eisai Inc.
11.7.1 Eisai Inc. Company Information
11.7.2 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
11.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Eisai Inc. Main Business Overview
11.7.5 Eisai Inc. Latest Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Company Information
11.8.2 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Offered
11.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Eli Lilly Main Business Overview
11.8.5 Eli Lilly Latest Developments
11.9 Green Valley
11.9.1 Green Valley Company Information
11.9.2 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Offered
11.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Green Valley Main Business Overview
11.9.5 Green Valley Latest Developments
11.10 NOVARTIS
11.10.1 NOVARTIS Company Information
11.10.2 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Offered
11.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 NOVARTIS Main Business Overview
11.10.5 NOVARTIS Latest Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Information
11.11.2 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Offered
11.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Bristol-Myers Squibb Main Business Overview
11.11.5 Bristol-Myers Squibb Latest Developments
11.12 Janssen
11.12.1 Janssen Company Information
11.12.2 Janssen Targeted Drugs for Neurodegenerative Diseases Product Offered
11.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Janssen Main Business Overview
11.12.5 Janssen Latest Developments
11.13 Sanofi
11.13.1 Sanofi Company Information
11.13.2 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Offered
11.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Sanofi Main Business Overview
11.13.5 Sanofi Latest Developments
11.14 Roche
11.14.1 Roche Company Information
11.14.2 Roche Targeted Drugs for Neurodegenerative Diseases Product Offered
11.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Roche Main Business Overview
11.14.5 Roche Latest Developments
11.15 Neurocrine
11.15.1 Neurocrine Company Information
11.15.2 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Offered
11.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Neurocrine Main Business Overview
11.15.5 Neurocrine Latest Developments
11.16 Lundbeck
11.16.1 Lundbeck Company Information
11.16.2 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Offered
11.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Lundbeck Main Business Overview
11.16.5 Lundbeck Latest Developments
11.17 Teva
11.17.1 Teva Company Information
11.17.2 Teva Targeted Drugs for Neurodegenerative Diseases Product Offered
11.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Teva Main Business Overview
11.17.5 Teva Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)
2.1.2 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted Drugs for Neurodegenerative Diseases by Country/Region (2021, 2025 & 2032)
2.2 Targeted Drugs for Neurodegenerative Diseases Segment by Type
2.2.1 Injection
2.2.2 Oral
2.2.3 Targeted Drugs for Neurodegenerative Diseases Market Size by Type
2.2.3.1 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
2.3 Targeted Drugs for Neurodegenerative Diseases Segment by Application
2.3.1 Parkinson's Disease (PD)
2.3.2 Alzheimer's Disease (AD)
2.3.3 Huntington's Disease (HD)
2.3.4 Tardive Dyskinesia (TD)
2.3.5 Multiple Sclerosis (MS)
2.3.6 Targeted Drugs for Neurodegenerative Diseases Market Size by Application
2.3.6.1 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.6.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
3 TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES MARKET SIZE BY PLAYER
3.1 Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Player
3.1.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Player (2021-2026)
3.1.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
3.2 Global Targeted Drugs for Neurodegenerative Diseases Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES BY REGION
4.1 Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026)
4.2 Global Targeted Drugs for Neurodegenerative Diseases Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.4 APAC Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.5 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
5.2 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
5.3 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026)
6.2 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
6.3 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
7.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases by Region (2021-2026)
8.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES MARKET FORECAST
10.1 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.1 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.1.2 Americas Targeted Drugs for Neurodegenerative Diseases Forecast
10.1.3 APAC Targeted Drugs for Neurodegenerative Diseases Forecast
10.1.4 Europe Targeted Drugs for Neurodegenerative Diseases Forecast
10.1.5 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Forecast
10.2 Americas Targeted Drugs for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.2.1 United States Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.2.2 Canada Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.2.3 Mexico Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.2.4 Brazil Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3 APAC Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.3.1 China Targeted Drugs for Neurodegenerative Diseases Market Forecast
10.3.2 Japan Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.3 Korea Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.4 Southeast Asia Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.5 India Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.3.6 Australia Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4 Europe Targeted Drugs for Neurodegenerative Diseases Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.2 France Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.3 UK Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.4 Italy Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.4.5 Russia Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5.2 South Africa Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5.3 Israel Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.5.4 Turkey Market Targeted Drugs for Neurodegenerative Diseases Forecast
10.6 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Type (2027-2032)
10.7 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted Drugs for Neurodegenerative Diseases Forecast
11 KEY PLAYERS ANALYSIS
11.1 Acadia Pharmaceuticals Inc.
11.1.1 Acadia Pharmaceuticals Inc. Company Information
11.1.2 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Acadia Pharmaceuticals Inc. Main Business Overview
11.1.5 Acadia Pharmaceuticals Inc. Latest Developments
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Company Information
11.2.2 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Offered
11.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Kyowa Kirin Main Business Overview
11.2.5 Kyowa Kirin Latest Developments
11.3 Supernus Pharmaceuticals
11.3.1 Supernus Pharmaceuticals Company Information
11.3.2 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Offered
11.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Supernus Pharmaceuticals Main Business Overview
11.3.5 Supernus Pharmaceuticals Latest Developments
11.4 UCB
11.4.1 UCB Company Information
11.4.2 UCB Targeted Drugs for Neurodegenerative Diseases Product Offered
11.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 UCB Main Business Overview
11.4.5 UCB Latest Developments
11.5 Sumitomo Pharma
11.5.1 Sumitomo Pharma Company Information
11.5.2 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Offered
11.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Sumitomo Pharma Main Business Overview
11.5.5 Sumitomo Pharma Latest Developments
11.6 Biogen
11.6.1 Biogen Company Information
11.6.2 Biogen Targeted Drugs for Neurodegenerative Diseases Product Offered
11.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Biogen Main Business Overview
11.6.5 Biogen Latest Developments
11.7 Eisai Inc.
11.7.1 Eisai Inc. Company Information
11.7.2 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
11.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Eisai Inc. Main Business Overview
11.7.5 Eisai Inc. Latest Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Company Information
11.8.2 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Offered
11.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Eli Lilly Main Business Overview
11.8.5 Eli Lilly Latest Developments
11.9 Green Valley
11.9.1 Green Valley Company Information
11.9.2 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Offered
11.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Green Valley Main Business Overview
11.9.5 Green Valley Latest Developments
11.10 NOVARTIS
11.10.1 NOVARTIS Company Information
11.10.2 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Offered
11.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 NOVARTIS Main Business Overview
11.10.5 NOVARTIS Latest Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Information
11.11.2 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Offered
11.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Bristol-Myers Squibb Main Business Overview
11.11.5 Bristol-Myers Squibb Latest Developments
11.12 Janssen
11.12.1 Janssen Company Information
11.12.2 Janssen Targeted Drugs for Neurodegenerative Diseases Product Offered
11.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Janssen Main Business Overview
11.12.5 Janssen Latest Developments
11.13 Sanofi
11.13.1 Sanofi Company Information
11.13.2 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Offered
11.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Sanofi Main Business Overview
11.13.5 Sanofi Latest Developments
11.14 Roche
11.14.1 Roche Company Information
11.14.2 Roche Targeted Drugs for Neurodegenerative Diseases Product Offered
11.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Roche Main Business Overview
11.14.5 Roche Latest Developments
11.15 Neurocrine
11.15.1 Neurocrine Company Information
11.15.2 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Offered
11.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Neurocrine Main Business Overview
11.15.5 Neurocrine Latest Developments
11.16 Lundbeck
11.16.1 Lundbeck Company Information
11.16.2 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Offered
11.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Lundbeck Main Business Overview
11.16.5 Lundbeck Latest Developments
11.17 Teva
11.17.1 Teva Company Information
11.17.2 Teva Targeted Drugs for Neurodegenerative Diseases Product Offered
11.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Teva Main Business Overview
11.17.5 Teva Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted Drugs for Neurodegenerative Diseases Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Injection
Table 4. Major Players of Oral
Table 5. Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 8. Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 11. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
Table 13. Targeted Drugs for Neurodegenerative Diseases Key Players Head office and Products Offered
Table 14. Targeted Drugs for Neurodegenerative Diseases Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 19. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 23. Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 25. Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 27. APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 29. APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 33. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Targeted Drugs for Neurodegenerative Diseases
Table 39. Key Market Challenges & Risks of Targeted Drugs for Neurodegenerative Diseases
Table 40. Key Industry Trends of Targeted Drugs for Neurodegenerative Diseases
Table 41. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Acadia Pharmaceuticals Inc. Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 46. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 47. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Acadia Pharmaceuticals Inc. Main Business
Table 49. Acadia Pharmaceuticals Inc. Latest Developments
Table 50. Kyowa Kirin Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 51. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 52. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Kyowa Kirin Main Business
Table 54. Kyowa Kirin Latest Developments
Table 55. Supernus Pharmaceuticals Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 56. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 57. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Supernus Pharmaceuticals Main Business
Table 59. Supernus Pharmaceuticals Latest Developments
Table 60. UCB Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 61. UCB Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 62. UCB Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. UCB Main Business
Table 64. UCB Latest Developments
Table 65. Sumitomo Pharma Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 66. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 67. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Sumitomo Pharma Main Business
Table 69. Sumitomo Pharma Latest Developments
Table 70. Biogen Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 71. Biogen Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 72. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Biogen Main Business
Table 74. Biogen Latest Developments
Table 75. Eisai Inc. Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 76. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 77. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Eisai Inc. Main Business
Table 79. Eisai Inc. Latest Developments
Table 80. Eli Lilly Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 81. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 82. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Eli Lilly Main Business
Table 84. Eli Lilly Latest Developments
Table 85. Green Valley Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 86. Green Valley Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 87. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Green Valley Main Business
Table 89. Green Valley Latest Developments
Table 90. NOVARTIS Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 91. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 92. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. NOVARTIS Main Business
Table 94. NOVARTIS Latest Developments
Table 95. Bristol-Myers Squibb Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 96. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 97. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Bristol-Myers Squibb Main Business
Table 99. Bristol-Myers Squibb Latest Developments
Table 100. Janssen Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 101. Janssen Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 102. Janssen Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Janssen Main Business
Table 104. Janssen Latest Developments
Table 105. Sanofi Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 106. Sanofi Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 107. Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Sanofi Main Business
Table 109. Sanofi Latest Developments
Table 110. Roche Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 111. Roche Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 112. Roche Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Roche Main Business
Table 114. Roche Latest Developments
Table 115. Neurocrine Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 116. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 117. Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Neurocrine Main Business
Table 119. Neurocrine Latest Developments
Table 120. Lundbeck Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 121. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 122. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Lundbeck Main Business
Table 124. Lundbeck Latest Developments
Table 125. Teva Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 126. Teva Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 127. Teva Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Teva Main Business
Table 129. Teva Latest Developments
Table 1. Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted Drugs for Neurodegenerative Diseases Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Injection
Table 4. Major Players of Oral
Table 5. Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 8. Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 11. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player (2021-2026)
Table 13. Targeted Drugs for Neurodegenerative Diseases Key Players Head office and Products Offered
Table 14. Targeted Drugs for Neurodegenerative Diseases Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 19. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 23. Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Table 25. Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Table 27. APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Table 29. APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country (2021-2026)
Table 33. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Targeted Drugs for Neurodegenerative Diseases
Table 39. Key Market Challenges & Risks of Targeted Drugs for Neurodegenerative Diseases
Table 40. Key Industry Trends of Targeted Drugs for Neurodegenerative Diseases
Table 41. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Acadia Pharmaceuticals Inc. Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 46. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 47. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Acadia Pharmaceuticals Inc. Main Business
Table 49. Acadia Pharmaceuticals Inc. Latest Developments
Table 50. Kyowa Kirin Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 51. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 52. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Kyowa Kirin Main Business
Table 54. Kyowa Kirin Latest Developments
Table 55. Supernus Pharmaceuticals Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 56. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 57. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Supernus Pharmaceuticals Main Business
Table 59. Supernus Pharmaceuticals Latest Developments
Table 60. UCB Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 61. UCB Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 62. UCB Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. UCB Main Business
Table 64. UCB Latest Developments
Table 65. Sumitomo Pharma Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 66. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 67. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Sumitomo Pharma Main Business
Table 69. Sumitomo Pharma Latest Developments
Table 70. Biogen Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 71. Biogen Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 72. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Biogen Main Business
Table 74. Biogen Latest Developments
Table 75. Eisai Inc. Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 76. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 77. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Eisai Inc. Main Business
Table 79. Eisai Inc. Latest Developments
Table 80. Eli Lilly Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 81. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 82. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Eli Lilly Main Business
Table 84. Eli Lilly Latest Developments
Table 85. Green Valley Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 86. Green Valley Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 87. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Green Valley Main Business
Table 89. Green Valley Latest Developments
Table 90. NOVARTIS Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 91. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 92. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. NOVARTIS Main Business
Table 94. NOVARTIS Latest Developments
Table 95. Bristol-Myers Squibb Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 96. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 97. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Bristol-Myers Squibb Main Business
Table 99. Bristol-Myers Squibb Latest Developments
Table 100. Janssen Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 101. Janssen Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 102. Janssen Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Janssen Main Business
Table 104. Janssen Latest Developments
Table 105. Sanofi Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 106. Sanofi Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 107. Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Sanofi Main Business
Table 109. Sanofi Latest Developments
Table 110. Roche Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 111. Roche Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 112. Roche Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Roche Main Business
Table 114. Roche Latest Developments
Table 115. Neurocrine Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 116. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 117. Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Neurocrine Main Business
Table 119. Neurocrine Latest Developments
Table 120. Lundbeck Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 121. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 122. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Lundbeck Main Business
Table 124. Lundbeck Latest Developments
Table 125. Teva Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors
Table 126. Teva Targeted Drugs for Neurodegenerative Diseases Product Offered
Table 127. Teva Targeted Drugs for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Teva Main Business
Table 129. Teva Latest Developments
LIST OF FIGURES
Figure 1. Targeted Drugs for Neurodegenerative Diseases Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted Drugs for Neurodegenerative Diseases Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Country/Region (2025)
Figure 8. Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type in 2025
Figure 10. Targeted Drugs for Neurodegenerative Diseases in Parkinson's Disease (PD)
Figure 11. Global Targeted Drugs for Neurodegenerative Diseases Market: Parkinson's Disease (PD) (2021-2026) & ($ millions)
Figure 12. Targeted Drugs for Neurodegenerative Diseases in Alzheimer's Disease (AD)
Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Market: Alzheimer's Disease (AD) (2021-2026) & ($ millions)
Figure 14. Targeted Drugs for Neurodegenerative Diseases in Huntington's Disease (HD)
Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Market: Huntington's Disease (HD) (2021-2026) & ($ millions)
Figure 16. Targeted Drugs for Neurodegenerative Diseases in Tardive Dyskinesia (TD)
Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Market: Tardive Dyskinesia (TD) (2021-2026) & ($ millions)
Figure 18. Targeted Drugs for Neurodegenerative Diseases in Multiple Sclerosis (MS)
Figure 19. Global Targeted Drugs for Neurodegenerative Diseases Market: Multiple Sclerosis (MS) (2021-2026) & ($ millions)
Figure 20. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application in 2025
Figure 21. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player in 2025
Figure 22. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 23. Americas Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 24. APAC Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 25. Europe Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 27. Americas Targeted Drugs for Neurodegenerative Diseases Value Market Share by Country in 2025
Figure 28. United States Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region in 2025
Figure 33. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 34. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 35. China Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 39. India Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country in 2025
Figure 42. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 43. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 44. Germany Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 45. France Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 58. APAC Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 59. Europe Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 61. United States Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 62. Canada Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 63. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 64. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 65. China Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 66. Japan Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 67. Korea Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 69. India Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 70. Australia Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 71. Germany Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 72. France Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 73. UK Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 74. Italy Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 75. Russia Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 76. Egypt Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 77. South Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 78. Israel Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 79. Turkey Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 80. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 1. Targeted Drugs for Neurodegenerative Diseases Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted Drugs for Neurodegenerative Diseases Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Country/Region (2025)
Figure 8. Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type in 2025
Figure 10. Targeted Drugs for Neurodegenerative Diseases in Parkinson's Disease (PD)
Figure 11. Global Targeted Drugs for Neurodegenerative Diseases Market: Parkinson's Disease (PD) (2021-2026) & ($ millions)
Figure 12. Targeted Drugs for Neurodegenerative Diseases in Alzheimer's Disease (AD)
Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Market: Alzheimer's Disease (AD) (2021-2026) & ($ millions)
Figure 14. Targeted Drugs for Neurodegenerative Diseases in Huntington's Disease (HD)
Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Market: Huntington's Disease (HD) (2021-2026) & ($ millions)
Figure 16. Targeted Drugs for Neurodegenerative Diseases in Tardive Dyskinesia (TD)
Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Market: Tardive Dyskinesia (TD) (2021-2026) & ($ millions)
Figure 18. Targeted Drugs for Neurodegenerative Diseases in Multiple Sclerosis (MS)
Figure 19. Global Targeted Drugs for Neurodegenerative Diseases Market: Multiple Sclerosis (MS) (2021-2026) & ($ millions)
Figure 20. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application in 2025
Figure 21. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player in 2025
Figure 22. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 23. Americas Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 24. APAC Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 25. Europe Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2021-2026 ($ millions)
Figure 27. Americas Targeted Drugs for Neurodegenerative Diseases Value Market Share by Country in 2025
Figure 28. United States Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region in 2025
Figure 33. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 34. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 35. China Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 39. India Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country in 2025
Figure 42. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 43. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 44. Germany Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 45. France Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 58. APAC Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 59. Europe Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 61. United States Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 62. Canada Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 63. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 64. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 65. China Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 66. Japan Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 67. Korea Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 69. India Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 70. Australia Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 71. Germany Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 72. France Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 73. UK Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 74. Italy Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 75. Russia Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 76. Egypt Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 77. South Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 78. Israel Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 79. Turkey Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
Figure 80. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Targeted Drugs for Neurodegenerative Diseases Market Size 2027-2032 ($ millions)
